, and regulating the number, viability, distribution, phenotype and 'non-immune' functions of structural cells, such as fibroblasts and vascular endothelial cells. Mast cells can exert their effector functions through the direct or indirect actions of a wide variety of mast-cell-derived products, and such functions can be observed in both innate [1] [2] [3] 12 and adaptive 1, 5, 6, 12, 13 immune responses
.
Mast cells can also influence many aspects of the biology of immune cells, including granulocytes, monocytes/macrophages, dendritic cells (DCs), T cells, B cells, natural killer (NK) cells and NKT cells. In this case, the effects of mast cells on the recruitment, survival, development, phenotype or function of immune cells are referred to as 'immunomodulatory' functions
Through their effector and/or immunomodulatory functions, mast cells can promote the initiation and increase the magnitude of inflammation, tissue remodelling and, in some cases, tissue injury associated with the innate or adaptive immune response to pathogens, as well as during allergic and autoimmune disorders [1] [2] [3] [5] [6] [7] 13 . Given the many mechanisms by which mast cells can mediate these immunostimulatory effects, the main role of mast cells is often thought to be to turn on an immune response. However, as described here, mast cells also have functions that can decrease inflammation, tissue remodelling and tissue injury. Accordingly, a new picture of the function of mast cells is emerging; these cells have the potential to turn immune responses off, as well as to turn them on. Unlike the specific regulatory T-cell subset 14 , there is no evidence so far to indicate the existence of a specific developmentally and phenotypically distinct subset of immunoregulatory mast cells with specific immunosuppressive functions. Accordingly, we refer to the anti-inflammatory and immunosuppressive functions of mast cells as 'negative immunomodulatory' functions, and to those functions that increase the initiation, magnitude or duration of an immune response as 'positive immunomodulatory' functions
In this Opinion article, we highlight some basic aspects of mast-cell biology and briefly discuss some of the functions, products and surface receptors of mast cells that contribute to their immunomodulatory function (reviewed in REFS 1, 3, 5, 6, 13) . We describe the mouse models that are used to analyse mast-cell function in vivo and to identify immunomodulatory roles for mast cells during specific immune responses.
On the basis of this evidence, we present three hypotheses regarding the immunomodulatory properties of mast cells. First, that the potential to carry out negative, as well as positive, immunomodulatory functions is a basic property of the mast-cell lineage. Second, that mast cells can both enhance and later help to limit certain innate and adaptive immune responses. Third, that the extent to which mast cells actually carry out such positive or negative immunomodulatory functions during specific immune responses in vivo is highly dependent on the individual biological setting.
The basic biology of mast cells
Origin and tissue distribution. Mast cells are derived from haematopoietic stem cells, but they do not ordinarily circulate in a mature form; instead, differentiation and maturation occur locally, following the migration of mast-cell precursors to the vascularized tissues or serosal cavities in which mast cells will ultimately reside [15] [16] [17] ( FIG. 1) . In vertebrates, mast cells are widely distributed throughout the vascularized tissues, in particular near surfaces that are exposed to the environment, including the skin, airways and gastrointestinal tract, where pathogens, allergens and other environmental agents are frequently encountered [15] [16] [17] . Thereby, mast cells, together with DCs, are well-positioned to be one of the first cell types of the immune system to interact with environmental antigens and allergens, invading pathogens, or environmentally derived toxins.
Mast cells are long-lived cells that, similar to monocytes and macrophages, can re-enter the cell cycle and proliferate following appropriate stimulation. Increased recruitment and/or retention, as well as the local maturation of mast-cell progenitors, can also contribute to the expansion of mast-cell populations in the tissue [15] [16] [17] [18] (FIG. 1) . In addition, an increase in the number of mast cells, as well as local changes in their tissue distribution and/or phenotypical characteristics, can occur during T helper 2 (T H 2)-cell responses, persistent inflammation and/or tissue remodelling [15] [16] [17] [18] (FIG. 1) . Such T H 2-cell responses are often associated also with an increase in the number of circulating basophils, which are haematopoietic cells that are developmentally distinct from mast cells but that can secrete various mediators, including histamine, that are also produced by mast cells.
Both the regulation of mast-cell survival and proliferation and the modulation of important phenotypical characteristics of mast cells -including their susceptibility to activation by various stimuli during innate or adaptive immune responses, their ability to store and/or produce various secreted products, and the magnitude and nature of the secretory response of mast cells to specific activation stimuli -can be finely controlled or 'tuned'
1 . The main survival and developmental factor for mast cells is stem-cell factor (SCF; also known as KIT ligand), but many growth factors, cytokines and chemokines can influence the number and phenotype of mast cells, including interleukin-3 (Il-3), which is of particular importance in mice, T H 2-cell-associated cytokines (such as Il-4 and Il-9) and transforming growth factor-β1 (TGFβ1) [15] [16] [17] [18] [19] . Activation and secretion of products. various stimuli, in addition to Ige and specific antigen, can activate mast cells to release a wide variety of biologically active products, many of which can potentially mediate proinflammatory, anti-inflammatory and/or immunosuppressive functions (summarized in REFS 1, 2, 6, 13) . Furthermore, mast cells can participate in multiple cycles of activation for mediator release and can be differentially activated to release distinct patterns of mediators or cytokines, depending on the type and strength of the activating stimuli 1, 6, 13, 18, 20, 21 . The strength and nature of the responsiveness of mast cells to various activating stimuli can be influenced by genetic and microenvironmental factors that affect the expression pattern or functional properties of the surface receptors or signalling molecules that contribute to such responses 1, 4, 20 . Accordingly, it can be problematic to generalize findings from studies of a single mast-cell population -such as phenotypically 'immature' mast cells derived in vitro from mouse haematopoietic stem cells -to other mast-cell populations, such as mature mast cells in vivo. Also, although the co-incubation of mast cells with other cell types under defined conditions in vitro is possible (and this has provided very valuable information on the nature and potential importance of such interactions), it is exceedingly difficult (and probably impossible) to recapitulate fully in vitro the conditions that are experienced by mast cells in vivo. For this reason, we think that to understand the functions of mast cells during health and disease, these cells should also be studied in vivo. 
Examples:
• Promote the clearance of pathogens by phagocytosis and/or the secretion of anti-microbial peptides;
• Degrade potentially toxic endogenous peptides and components of venoms;
• Increase vascular permeability (for example, by the release of histamine);
• Stimulate bronchial smooth-muscle-cell contraction (for example, by the release of leukotriene C 4 (LTC 4 ));
• Promote collagen synthesis by fibroblasts (for example, by the release of tryptase). 
Immunomodulatory functions

Examples of positive immunomodulatory functions:
• Promote the migration, maturation, differentiation and function of immune cells through the secretion of factors such as tumour-necrosis factor (TNF), chemokines, histamine, LTB 4 and proteases;
• Present antigen to T cells (on MHC class I or II molecules) or increase antigen presentation by capturing IgE-bound antigens through FcεRI and then undergoing apoptosis;
• Promote the production of IgE by B cells (through the secretion of interleukin-4 (IL-4), IL-13 and CD40L);
• Promote the expression of thymic stromal lymphopoietin (TSLP) by epithelial cells (for example, through the secretion of TNF, IL-4 and IL-13);
• Promote the recruitment of immune cells by the production of TNF and other mediators that upregulate the expression of adhesion molecules by vascular endothelial cells;
• Promote T helper 2 (T H 2)-cell responses through the effects of prostaglandin D 2 on DC maturation;
• Promote the production of chemokines and cytokines by airway smooth muscle cells (through the secretion of TNF, IL-4 and IL-13).
Examples of negative immunomodulatory functions:
• Suppress sensitization for contact hypersensitivity (through ultraviolet-B-light-induced production of histamine);
• Suppress cytokine production by T cells and monocytes (through the secretion of IL-10);
• Suppress the production of pro-inflammatory cytokines and chemokines by keratinocytes (through the secretion of IL-10);
• Enhance the ability of DCs to decrease T-cell proliferation and cytokine production (through the secretion of IL-10). Differences in the biological responses of Kit-mutant mice compared with wildtype mice might be due to any one of the abnormalities that result from the Kit mutations in these animals and they might not be specifically due to the loss of mast cells. However, the lack of mast cells in Kit-mutant mice can be selectively repaired by the adoptive transfer of genetically compatible, in vitro-derived wild-type or mutant mast cells 1, 5, 15, 22 . Such in vitro-derived mast cells, for example bone-marrow-derived cultured mast cells, can be administered intravenously, intraperitoneally or intradermally, or can be injected directly into the anterior wall of the stomach of Kit-mutant mice, to create so-called mast-cell 'knock-in' mice. These mast-cell knock-in mice can then be used to assess the extent to which differences in the biological responses of Kit-mutant mice compared with wild-type mice are due to the lack of mast cells in the Kit-mutant mice.
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Other approaches. It is possible to investigate the role of specific mast-cell-associated mediators in vivo by studying animals in which that mediator has been knocked out. If a mediator is selectively expressed by mast cells, and if its deletion does not significantly influence the expression of other mast-cell products, then it is possible to draw conclusions about the role of that mast-cell mediator in vivo. For example, mice that lack mast-cell protease-1 (MCPT1) [26] [27] [28] , MCPT4 (REFS 29, 30) , tryptase β2 (TPSB2; also known as MCPT6) [31] [32] [33] or mast-cell carboxypeptidase A3 (CPA3; also known as MC-CPA) 34 , or that have a mutated form of CPA3 that essentially lacks enzymatic activity 11 , have been used to analyse whether the absence of these proteases (or their enzymatic activity) influences other aspects of the mast-cell phenotype, such as the content of other stored mediators, as well as to define the functions of such mast-cell-associated proteases in vivo.
Other promising genetic approaches to investigate the specific functions of mast cells and their products are currently in development, such as mast-cell-specific Crerecombinase-expressing mice, which could be crossed with other mouse strains in which the genes of interest are 'floxed' 35 . When a gene segment is flanked by loxP sites (floxed), Cre recombinase, which recognizes the loxP consensus sequence, can excise that specific segment from the gene sequence. Such approaches will be useful to analyse to what extent mast cells are an important source of products with potential immunomodulatory effects that can also be derived from other cell types, such as histamine, leukotrienes, prostaglandins, cytokines and chemokines.
Pharmacological approaches or those based on the use of antibodies to deplete mast cells or to neutralize their products can also provide useful information, but they are limited by the specificity of the drug or antibody chosen. For example, antihistamines block the actions of histamine whether it has been secreted by mast cells or by non-mast cells, and antibodies that neutralize SCF 36 or block KIT 37, 38 can result in the depletion of mast cells in vivo, but can also influence other cell types that express KIT.
Drugs (or antibodies) that only interfere with mast-cell activation would be highly desirable for experimental studies and, possibly, for evaluation as therapeutic agents. One such drug, disodium cromoglycate, is widely characterized as a mast-cell 'stabilizer' (that is, an agent that blocks the release of mast-cell mediators following appropriate activation of the cell) and it has been used in efforts to suppress mouse mast-cell function in vivo 39, 40 . However, the molecular targets of this drug are not restricted to mast cells 41 and disodium cromoglycate also influences the function of granulocytes and B cells 42 . Given the current limitations of the use of pharmacological or McPs circulate in the blood and enter the tissues, where they undergo differentiation and maturation to become mature mast cells. stem-cell factor (scF; also known as KIt ligand) is normally required to ensure mast-cell survival in the tissues, but the phenotype of mature mast cells can vary depending on the growth-factor milieu -for example, the presence or absence of additional cytokines with effects on mast-cell proliferation or phenotype, such as interleukin-3 (IL-3), IL-4, IL-9 and transforming growth factor-β1 -and other microenvironmental factors. For example, mucosal mast cells are found in the mucosa of the gut, whereas connective-tissue mast cells, which have certain phenotypical characteristics that differ from those of mucosal mast cells, reside in the submucosa and muscularis propria. the size of these mast-cell populations can increase markedly during a t helper 2 (t H 2)-cell response to parasitic infection of the gut, which might be due to a combination of increased recruitment, survival and/or differentiation and maturation of McPs, as well as the proliferation of mast cells that are resident at that site. FcεrI, high-affinity Fc receptor for IgE; FcγrII/III, low-affinity activating (FcγrIII) and inhibitory (FcγrIIβ) Fc receptors for IgG; IL-3r, IL-3 receptor.
antibody-based approaches to eliminate mast cells or to specifically block their functional activation, we think that genetic approaches (including mast-cell knock-in mice, mice deficient in specific mast-cell-associated mediators and, if fully validated, approaches that genetically delete specific mediators selectively in mast cells) will be the most definitive way to identify and characterize mast-cell functions in vivo.
Mast-cell immunomodulatory functions
Immunomodulatory activity in vitro. Mast cells express MHC class I and II molecules, and they have been reported to process and present antigen in vitro (reviewed in REFS 13, [43] [44] [45] . Mast cells can also increase antigen presentation in vitro by internalizing Ige-bound antigen through the high-affinity Fc receptor for Ige (FcεrI); this mechanism is independent of MHC class II expression by the mast cell, but it requires mast-cell apoptosis and phagocytosis by other antigenpresenting cells, which then present the antigen 45 . However, so far there is no evidence from in vivo studies to indicate that mast cells present antigen during naturally occurring or experimental immune responses.
The expression of various co-stimulatory molecules by mast cells is further evidence that these cells can have immunomodulatory roles. The co-stimulatory molecules expressed by mouse and/or human mast cells include members of the B7 family, members of the tumour-necrosis factor (TNF) and TNF receptor families, CD28 and CD40 ligand (CD40l) 6 . Some individual mediators, such as histamine, can have both positive and negative immunomodulatory effects. Histamine, which can be produced by mast cells and other immune cells, can promote T H 1-cell activation through the H1 receptor, but can also suppress both T H 1-and T H 2-cell activation through the H2 receptor 50 . Mast cells can also produce cytokines that influence the polarization and function of T-cell subsets 1, 5, 6, 13, 43 . However, there is only one study showing that such an effect of a mast-cell-derived cytokine on T cells is important in vivo (see below) 54 . Similarly, several mast-cell products, including Il-4, Il-5, Il-6, Il-13, CD40l and rat MCPT1, can influence B-cell development and function, including Ige production 6, 13 . However, the in vivo relevance of these observations remains to be determined.
Positive immunomodulatory functions in vivo.
Some of the positive immunomodulatory functions of mast cells that have been proposed based on in vitro studies have been confirmed in vivo using mast-cell knock-in mice 1, 54, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] or mice lacking specific mast-cell-associated proteases [26] [27] [28] [32] [33] [34] or lacking specific protease enzymatic activity 11 (TABLE 1). In many of these studies, the end *representative functions were shown in experiments carried out in vivo using either mast-cell-protease-deficient mice or mast-cell-engrafted Kit-mutant mice (mast-cell knock-in mice). In some models using mast-cell knock-in mice, the main mast-cell mediators with immunomodulatory functions in that model have not yet been defined. Not included here are many examples of studies using mast-cell knock-in mice that have shown pro-inflammatory effects of mast cells (for example, the promotion of leukocyte recruitment), but in which the main mast-cell-associated mediators have not yet been defined in vivo. † In some of the referenced studies, the mast-cell mediators that contribute to the function listed have not yet been identified. § Not yet shown using mast-cell knock-in mice. cHs, contact hypersensitivity; cXcL2, cXc-chemokine ligand 2; Dc, dendritic cell; EAE, experimental autoimmune encephalomyelitis; FcεrI, high-affinity Fc receptor for IgE; IL, interleukin; McPt1, mast-cell protease-1; ND, not determined; t H 1, t helper 1; tNF, tumour-necrosis factor; tPsB2, tryptase B2 (also known as McPt6); UvB, ultraviolet B. Mast cells have been shown to be crucial for host survival in models of bacterial infection 59, [73] [74] [75] [76] and, in some of these models, there was evidence that TNF promoted survival 59, 73, 74 . However, the extent to which such TNF was produced by mast cells was not specifically analysed in these studies. In addition, there is evidence that mast cells might be able to promote host survival in the cecal ligation and puncture (ClP) model of bacterial infection by TNF-independent mechanisms in mice that lack TNF 74 . In addition to their role in bacterial infections, mast cells can also promote host resistance to certain parasite infections. However, the mechanisms involved have not been fully defined and might be complex, involving both local and systemic mast-cell-dependent effects (reviewed in REFS 1, 64, 77) .
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Several lines of evidence indicate that mast-cell-derived proteases can promote host defence in certain models of innate or adaptive immunity. Following intraperitoneal injection of the bacterium Klebsiella pneumoniae, TPSB2-deficient mice have both decreased neutrophil recruitment to the peritoneal cavity and significantly increased mortality 32 . A deficiency of TPSB2 (or of Ige) was also associated with markedly decreased recruitment of eosinophils to the sites of larvae deposition in skeletal muscle during the chronic phase of Trichinella spiralis infection, but TPSB2 or Ige deficiency was not associated with a detectable abnormality in the intestinal expulsion of the parasite 33 . recent evidence indicates that MCPT2 can contribute to neutrophil recruitment and host survival during ClP in mice, but that in wild-type mice, mast-cell production of intracellular Il-15 ordinarily limits the ability of mast cells to produce MCPT2 in that setting 76 . In a myelin oligodendrocyte glycoprotein (MOG)-induced model of experimental autoimmune encephalomyelitis (eAe), mast cells can increase the incidence and severity of the disease 6, 78 . remarkably, it seems that mast cells do not have to be present in the central nervous system (CNS) to exert at least some of their important effects in MOG-induced eAe. Therefore, although systemic engraftment of Kit W/W-v mice with in vitro-derived, bone-marrowderived cultured mast cells does not result in the presence of mast cells in the CNS of these mice, disease severity in the CNS of engrafted mice is similar to that of wildtype mice. One way in which the activity of mast cells outside of the CNS can influence autoimmune responses to MOG is through the production of Il-4 in the lymph nodes, which promotes the development of encephalitogenic T H 1 cells 54 . Mast-cell-derived TNF contributes to airway hyper-reactivity and inflammation in models of allergic airway inflammation 67, 70, 79 , probably in part due to its ability to promote T-cell recruitment 67, 70 and to increase local levels of Il-4, Il-5, Il-13 and Il-17 (REF. 67 ). Mast cells can also make a substantial contribution to disease pathology in models of autoantibody-induced destructive arthritis 80 , bullous pemphigoid (an autoimmune disease of the skin 81 ) and T H 17-cell-dependent, neutrophil-associated lung inflammation 68 . In summary, mast cells can have positive immunoregulatory functions in vivo that can either enhance host defence or promote disease, that reflect the actions of the stored mediators and/or cytokines of mast cells and that can be mediated by mast cells that reside either at the site of the immune response or in lymph nodes.
Negative immunomodulatory functions in vivo.
It has been reported that mast cells also have immunomodulatory functions that significantly decrease the magnitude or duration of the immune response. Hart et al. 49 showed that the ability of ultraviolet B (UvB) irradiation of the skin to induce systemic immunosuppression of + t cells) and inhibit the migration, maturation and activation of dendritic cells (Dcs). IL-10 can also increase the ability of Dcs to inhibit t-cell proliferation and cytokine production through the downregulation of expression of co-stimulatory molecules by the Dcs. By directly inhibiting tumour-necrosis factor (tNF) and IL-6 production by keratinocytes, IL-10 can indirectly decrease the expression of adhesion molecules on vascular endothelial cells and thereby decrease the recruitment of circulating effector cells. IL-10 can directly inhibit the production of prostanoids by neutrophils and pro-inflammatory cytokines by macrophages. Although many of the specific functions indicated are based on evidence from in vitro studies of IL-10, mast-cellderived IL-10 has been shown to mediate negative immunomodulatory functions in vivo mice) promotes the migration of dendritic cells (Dcs) from the site of cutaneous sensitization to the draining lymph nodes. 1 day after epicutaneous challenge (that is, day 6 after sensitization), mast cells promote features of the effector phase of the response, such as swelling of the dermis and leukocyte recruitment, by directly or indirectly undergoing antigen-dependent activation and releasing mediators (including tumour-necrosis factor, tNF). In cHs response 1, mast cells have a net pro-inflammatory effect, by promoting both the sensitization and the effector phases of the response. the ability of mast cells to increase sensitization requires that the mast cells have antigen non-specific IgE bound to their high-affinity Fc receptor for IgE, FcεrI. the mechanism of mast-cell activation during the effector phase of the response is not clear. b | cHs response 2 is elicited by sensitizing mice epicutaneously on the abdomen with the hapten 2,4-dinitro-1-fluorobenzene DNFB (0.5% volume per volume) in 100% acetone and challenging them on the ear 5 days later with DNFB (0.2% volume per volume) in 100% acetone. One day after epicutaneous challenge with DNFB (that is, day 6 after sensitization), the ear-swelling responses are similar in the presence or absence of mast cells. therefore, mast-cell activation probably does not have a crucial role early after challenge. However, 5 days after epicutaneous challenge with the hapten, when the mice have increased circulating levels of antigen-specific IgG 1 antibodies, mast-cell-derived interleukin-10 (IL-10) contributes to the ability of mast cells to limit the number of innate inflammatory cells and t cells, as well as tissue pathology, at the site of hapten challenge. On the basis of in vitro studies, we speculate that increased local expression of certain cytokines (such as IL-4) at the site of hapten challenge can increase mast-cell surface expression of the low-affinity activating Fc receptor for IgG (FcγrIII), and perhaps have other effects on mast-cell phenotype and/or function. such mast cells can then secrete increased levels of tNF and IL-10 following stimulation through FcγrIII by immune complexes of specific antigen and IgG 1 antibodies. In the absence of mast cells (and mast-cell-derived IL-10), the pathology associated with this cHs response is markedly exacerbated and there is increased inflammation (including increased numbers of cD8 + , cD4 + and cD4 + cD25 + t cells), more marked thickening of the epidermis and more substantial increases in extracellular matrix (EcM) and other components of the dermis, as well as areas of full-thickness epidermal necrosis and ulceration. In cHs response 2, mast cells have a net anti-inflammatory effect.
contact hypersensitivity (CHS) responses to the hapten 2,4,6-trinitrochlorobenzene was markedly decreased in (C57Bl/6 × DBA/2)F1-Kit . Mast-cell-derived Il-10 was shown to limit many aspects of these responses, including the numbers of granulocytes, macrophages and T cells at the reaction sites, as well as local tissue swelling, epidermal hyperplasia and, importantly, full-thickness epidermal necrosis and ulceration. Although the mechanisms by which mast-cell-derived Il-10 (and other mast-cell mediators that are relevant in this setting) functions to limit the tissue changes in these models remain to be fully defined, mast cells and mast-cell-derived Il-10 might influence these responses through a complex combination of direct and indirect effector and immunoregulatory functions (FIG. 2) .
Mast cells also contribute to two other models of immunosuppression 82, 83 . Depinay et al. 82 reported that the bites of Anopheles mosquitoes can impair the development of antigen-specific T-cell responses in a model of DTH to ovalbumin in mice, but only if mast cells are present in the bitten skin. lu et al. 83 showed that mast cells are essential for the optimal induction of tolerance to skin allografts, which requires the participation of CD4
+ regulatory T cells. regulatory T cells are a source of Il-9, and Il-9 can suppress alloreactive CD8 + T cells and act as a mast-cell survival and/or growth factor (reviewed in REF. 83 ). The local production of Il-9 (by regulatory T cells and/or other sources) might contribute to the development, and perhaps influence the function, of mast cells in the tolerant allografts.
How mast cells mediate negative immunomodulatory effects following Anopheles mosquito bites, or in peripheral tolerance to skin allografts, remains to be fully elucidated. However, Il-10 was implicated as a mechanism of immunosuppression in each of these studies, acting either in the draining lymph nodes 82 or at the sites of skin allografts 83 . In addition, even though both T r 1 and CD4
+ regulatory T cells can develop in vivo in the absence of Il-10 (REF. 84 ), it will be of interest to assess whether mast cells and mast-cell-derived Il-10 have important effects on the number, phenotype and/or function of regulatory T cells in models of CHS or chronic UvB irradiation, or in other settings in which regulatory T cells are thought to have important roles [84] [85] [86] . In summary, through the production of Il-10 and probably other products, mast cells can have negative immunoregulatory functions in vivo that can markedly limit the magnitude and/or duration of both certain adaptive immune responses and the innate response to chronic irradiation with UvB light. (FIG. 3) .
Conclusions
One might speculate that in immune responses in which mast cells first promote the sensitization phase of the response, mast cells could then help to initiate the local inflammation that occurs when the host is subsequently exposed to specific antigen, and finally help to limit the extent of, and/or resolve, the ensuing inflammation and associated tissue pathology.
In support of this hypothesis, both in vitro and in vivo data strongly indicate that one of the mechanisms that can promote mast-cell-dependent Il-10 production, which in turn limits certain CHS responses, is the activation of mast cells through FcγrIII, presumably, by immune complexes of specific antigen and IgG 1 (REF. 23 ). These antigen-specific IgG 1 antibodies develop, probably by mast-cell-independent mechanisms, in response to the initial exposure to hapten during the sensitization phase of CHS 23 . So, in this model, the development of an aspect of the humoral response to hapten challenge (the production of antigen-specific IgG 1 ) results in the generation of a signal (presumably antigen-IgG 1 immune complexes) that promotes an anti-inflammatory phenotype in the mast cells that are resident at the site of the local reaction (FIG. 3b) . The idea that mast cells might first promote the sensitization and/or elicitation phases of an immune response, and then help to limit or resolve the local tissue changes induced by antigen challenge, is consistent with the hypothesis that an important function of mast cells is to promote homeostasis -even in circumstances when mast cells also have an important role in perturbing homeostasis to promote host defence [8] [9] [10] [11] . It will be of interest to understand how, and under what circumstances, the immunomodulatory functions of mast cells can influence the development, magnitude or kinetics of beneficial, or harmful, innate or adaptive immune responses. The extent to which the immunomodulatory effects of mast cells might contribute to some of the host-environment interactions that are thought to influence the development of the immune system (such as proposed in the hygiene hypothesis (reviewed in REF. 89 ), should also be explored.
Finally, it will be important to assess whether positive or negative immunoregulatory functions of mast cells can be therapeutically manipulated. One example of the possible therapeutic exploitation of a positive immunoregulatory function of mast cells might be the development of vaccine adjuvants that can enhance the induction of protective antigen-specific immune responses through the activation of mast cells to secrete TNF and other products at sites of vaccination with antigen 90 . It is also possible to envision therapeutic approaches that take advantage of the negative immunoregulatory functions of mast cells. For example, Il-10 is thought to make an important contribution to the effectiveness of antigen-specific immunotherapy (SIT) www.nature.com/reviews/immunol for allergic diseases, and successful SIT is associated with the development of a strong antigen-specific IgG 1 92 . Although it has not yet been reported whether IgG-dependent activation can induce the secretion of Il-10 by human mast cells, it is tempting to speculate that during SIT in humans, similar to CHS responses to urushiol or DNFB in mice, populations of mast cells are shifted from a net pro-inflammatory to a net anti-inflammatory phenotype, and that this change in mast-cell phenotype reflects, at least in part, the ability of immune complexes of specific antigen and IgG to stimulate mastcell Il-10 production. However, it remains to be seen whether this (or other) potential mast-cell-dependent immunoregulatory mechanism actually contributes to the success of standard SIT, or might be harnessed in other settings to enhance immune responses that promote health or to prevent or suppress those that result in disease.
